Vimarsana
Biggest News Aggregation in the World

Page 24 - Ar T News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ar T. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ar T Today - Breaking & Trending Today

Global CAR-T Therapy Market Report 2022-2026 & 2031: Focus - Vimarsana News

Global CAR-T Therapy Market Report 2022-2026 & 2031: Focus

Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) -- The "CAR-T Therapy Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The...

Correction - Autolus Therapeutics to Report Second Quarter - Vimarsana News

Correction - Autolus Therapeutics to Report Second Quarter

In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call,...

Developing safe and effective serial killers of solid tumors - Vimarsana News

Developing safe and effective serial killers of solid tumors

Discover how combining CAR T cell therapy and antibody engineering can improve the effectiveness of cancer immunotherapy

Patients Waiting Months for 'Last Chance' CAR T-Cell Therapy - Vimarsana News

Patients Waiting Months for 'Last Chance' CAR T-Cell Therapy

Supply shortages and limited manufacturing capacity are leaving myeloma patients waiting months for CAR T-cell therapy, which offers a "last chance" after all other therapies have failed.

BMS cancer drug's expanded approval gives it an edge over a Gilead cell therapy - Vimarsana News

BMS cancer drug's expanded approval gives it an edge over a Gilead cell therapy

The new FDA approval for Breyanzi moves the Bristol Myers Squibb cancer cell therapy into an earlier line of treatment for an aggressive type of blood cancer. The decision also gives the pharmaceutical giant access to an additional pool of patients untapped by a rival cell therapy from Gilead Sciences.